Delayed
Nasdaq
09:21:31 07/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
9.025
USD
|
+0.28%
|
|
+8.60%
|
-15.84%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
239
|
112.2
|
56.34
|
31.62
|
26.64
|
-
|
-
|
Enterprise Value (EV)
1 |
239
|
112.2
|
56.34
|
31.62
|
26.64
|
26.64
|
26.64
|
P/E ratio
|
-
|
-3.55
x
|
-1.19
x
|
-0.8
x
|
-0.84
x
|
-1.07
x
|
-1.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
70.8
x
|
26
x
|
37.8
x
|
40.3
x
|
49.6
x
|
39.5
x
|
35.5
x
|
EV / Revenue
|
70.8
x
|
26
x
|
37.8
x
|
40.3
x
|
49.6
x
|
39.5
x
|
35.5
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,438
|
2,471
|
2,817
|
2,948
|
2,960
|
-
|
-
|
Reference price
2 |
98.00
|
45.40
|
20.00
|
10.72
|
9.000
|
9.000
|
9.000
|
Announcement Date
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.375
|
4.315
|
1.49
|
0.785
|
0.5375
|
0.675
|
0.75
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.54
|
-31.37
|
-44.95
|
-41.71
|
-39.47
|
-49.32
|
-57.25
|
Operating Margin
|
-519.76%
|
-726.91%
|
-3,016.58%
|
-5,313.89%
|
-7,343.35%
|
-7,307.41%
|
-7,633.33%
|
Earnings before Tax (EBT)
1 |
-
|
-31.33
|
-44.17
|
-39.48
|
-37.23
|
-48.25
|
-56.25
|
Net income
1 |
-
|
-31.33
|
-44.17
|
-39.48
|
-37.83
|
-48.48
|
-56.25
|
Net margin
|
-
|
-726.14%
|
-2,964.43%
|
-5,029.17%
|
-7,038.93%
|
-7,181.48%
|
-7,500%
|
EPS
2 |
-
|
-12.80
|
-16.80
|
-13.43
|
-10.66
|
-8.440
|
-4.850
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2.128
|
0.556
|
0.746
|
0.191
|
0.382
|
0.171
|
0.203
|
0.106
|
0.179
|
0.297
|
0.1325
|
0.1325
|
0.1325
|
0.14
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.637
|
-8.08
|
-9.912
|
-11.8
|
-11.32
|
-11.92
|
-12.14
|
-9.545
|
-10.39
|
-9.636
|
-9.526
|
-9.53
|
-9.806
|
-10.61
|
Operating Margin
|
-452.87%
|
-1,453.24%
|
-1,328.69%
|
-6,175.39%
|
-2,964.66%
|
-6,967.84%
|
-5,981.77%
|
-9,004.72%
|
-5,804.47%
|
-3,244.44%
|
-7,189.62%
|
-7,192.45%
|
-7,400.75%
|
-7,577.32%
|
Earnings before Tax (EBT)
1 |
-
|
-8.073
|
-9.904
|
-11.74
|
-11.12
|
-11.4
|
-11.49
|
-8.966
|
-9.862
|
-9.164
|
-9.057
|
-8.96
|
-9.193
|
-10.02
|
Net income
1 |
-
|
-8.073
|
-9.904
|
-11.74
|
-11.12
|
-11.4
|
-11.49
|
-8.966
|
-9.862
|
-9.164
|
-9.08
|
-9.108
|
-9.407
|
-10.24
|
Net margin
|
-
|
-1,451.98%
|
-1,327.61%
|
-6,147.12%
|
-2,912.3%
|
-6,666.67%
|
-5,658.62%
|
-8,458.49%
|
-5,509.5%
|
-3,085.52%
|
-6,852.83%
|
-6,873.58%
|
-7,099.81%
|
-7,313.93%
|
EPS
2 |
-
|
-3.400
|
-4.000
|
-4.600
|
-4.200
|
-4.000
|
-4.000
|
-3.000
|
-3.400
|
-3.110
|
-2.878
|
-2.605
|
-2.618
|
-2.700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
10/03/22
|
05/05/22
|
09/08/22
|
03/11/22
|
09/03/23
|
04/05/23
|
10/08/23
|
09/11/23
|
07/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Average target price
30.67
USD Spread / Average Target +240.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.84% | 26.64M | | +19.75% | 46.81B | | -0.66% | 41.37B | | +47.07% | 41.29B | | -6.20% | 28.87B | | +11.85% | 26.06B | | -19.55% | 19.13B | | +32.94% | 12.39B | | +0.33% | 12.08B | | +0.18% | 11.96B |
Other Biotechnology & Medical Research
|